Gepirone

Gepirone

Systematic (IUPAC) name
4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
Clinical data
Pregnancy cat.	?
Legal status	Uncontrolled
Routes	Oral
Pharmacokinetic data
Half-life	2-3 hours
Identifiers
CAS number	83928-76-1
ATC code	N06AX19
PubChem	CID 55191
ChemSpider	49836 Y
UNII	JW5Y7B8Z18 Y
ChEMBL	CHEMBL284092 Y
Chemical data
Formula	C19H29N5O2
Mol. mass	359.46586 g/mol
SMILES O=C1N(C(=O)CC(C)(C)C1)CCCCN3CCN(c2ncccn2)CC3
InChI InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3 Y Key:QOIGKGMMAGJZNZ-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is a psychoactive drug and research chemical of the piperazine and azapirone chemical classes. It is currently under clinical development in an extended release form as an anxiolytic and antidepressant agent. Pharmacologically, gepirone acts as a selective 5-HT_1A receptor partial agonist.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. Fabre-Kramer and GlaxoSmithKline are evaluating the response from the FDA to determine appropriate next steps.

Ormaza, V. A.; 1986, ES 8606333 .

See also

• Azapirone